A study on evaluation duration and insurance admission of new traditional Chinese medicine drug approvals from 2014—2022

doi:10.3969/j.issn.1672-3384.2024.01.011

PDF(423 KB)

Clinical Medication Journal ›› 2024, Vol. 22 ›› Issue (1) : 51-55. DOI: 10.3969/j.issn.1672-3384.2024.01.011

A study on evaluation duration and insurance admission of new traditional Chinese medicine drug approvals from 2014—2022

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2024, 22(1): 51-55 https://doi.org/10.3969/j.issn.1672-3384.2024.01.011

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(423 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2023-08-12	2024-01-31
Issue Date
2024-01-31

Please choose a citation manager

Content to export